Clinical analysis of the Burkitt lymphoma
Jianhong Wang,Caixia Hao,Na Zhang,Weijing Jia,Baoxia Dong,Hongtao Gu,Lan Yang,Qingxian Bai,Tao Zhang,Guangxun Gao,Xiequn Chen,Rong Liang
DOI: https://doi.org/10.3969/j.issn.1672-4992.2016.23.031
2016-01-01
Abstract:Objective:To analyze the pathology,clinical features of 34 cases of Burkitt lymphoma(BL),confirmed in our center from 2007 to 2013,and the relationship between the treatment and curative effect in 12 cases.Methods:To retrospectively analyze the pathological data of 34 cases of BL diagnosed in our center 2007 -2013 (accounting for 1.43% of the total number of lymphoma in our hospital,accounting for 2.03% of B cell lymphoma)and the clinical data of 12 patients treated in our center.Chemotherapy [hyperCVAD(A +B)±R(rituximab)]±autologous hemato-poietic stem cell transplantation,observe the short -term remission rate[comoplete remission (CR)and partial remis-sion (PR)]and the long -term efficacy including 1 year and 2 years overall survival rate (OS),progression free sur-vival (PFS).Results:Male∶Female =10∶7 of 34 diagnosed patients,the median age was 23.5 years (3 ~74 years), 0 ~14 29.4%(10 /34),15 ~22 23.5%(8 /34),more than 22 47.1%(16 /34).It involves in various organs of the body (mainly in lymph nodes,brain and nasopharynx);Ki -67 index were greater than 95%.Among them,12 cases treated in our center,1 case (8.4%)in phase II,4 cases(33.3%)in stage III,seven cases (58.3%)in stage IV. Receiving treatment in 12 patients,1 case with bone marrow infiltration,after 1 course treatment of the VDCP chemo-therapy,disease progression,death.11 cases (91.7%)were take 3 course of the treatment of hyperCVAD (A +B) chemotherapy,2 cases partial remission (PR),9 cases complete remission (CR),the complete remission rate was 82%.In 9 cases of CR patients,1 case treated with CHOPE regimen chemotherapy,recurrence within 1 year,5 cases take hyperCVAD (A +B)to consolidate the 6 course of chemotherapy,1 case of recurrence after 1 year,the 2 year o-verall survival rate (OS)and progression free survival (PFS)were 100% and 80%.3 cases were taked hyperCVAD (A +B)+R regimen to consolidate the 6 course of chemotherapy,followed up for 2 years without recurrence,OS and PFS was 100% in 2 years,PFS was high compared with no R supplying.3 patients were taked the treatment of autolo-gous hematopoietic stem cell transplantation after 1 year of the consolidation and maintenance treatment,followed up for 2 years without recurrence,stable condition,OS and PFS were 100%.Among the patients(8 /11)with no recur-rence and stable disease during 2 year follow -up,less than 15 years of age accounted for 50%(4 /8),15 ~22 years old accounted for 37.5%(3 /8),more than 22 years old accounted for 12.5%(1 /8).Conclusion:Burkitt's lymphoma mainly occurs in children and adolescents,male is more than female,and it involves in various organs of the body.The diagnosis of clinical stage is often higher,chemotherapy with high strength,high frequency and regular,can improve the prognosis and raise the complete remission rate and total survival rate,especially to children and adolescents. Combined the consolidation of rituximab with autologous stem cell transplantation therapy can improve the rate of OS and PFS.